NO20062110L - Farmasoytiske formuleringer fremgangsmater og doseringsregimer for behandling og forebygging av akutte hjertesviktsyndromer. - Google Patents

Farmasoytiske formuleringer fremgangsmater og doseringsregimer for behandling og forebygging av akutte hjertesviktsyndromer.

Info

Publication number
NO20062110L
NO20062110L NO20062110A NO20062110A NO20062110L NO 20062110 L NO20062110 L NO 20062110L NO 20062110 A NO20062110 A NO 20062110A NO 20062110 A NO20062110 A NO 20062110A NO 20062110 L NO20062110 L NO 20062110L
Authority
NO
Norway
Prior art keywords
pharmaceutical formulations
prevention
treatment
heart failure
dosage regimens
Prior art date
Application number
NO20062110A
Other languages
English (en)
Other versions
NO339456B1 (no
Inventor
Charles Larry Bisgaier
Wendi Rodrigueza
Narendra D Lalwani
Daniel Hartman
Jan Johansson
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of NO20062110L publication Critical patent/NO20062110L/no
Publication of NO339456B1 publication Critical patent/NO339456B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen tilveiebringer fremgangsmåter og formuleringer for å behandle og å forebygge akutte koronare syndromer. Fremgangsmåtene i den foreliggende oppfinnelsen tilveiebringer trygge og effektive doser av et apolipoprotein A-I Milano:fosfolipidkompleks for å redusere og å stabilisere aterosklerotiske plakk. Farmasøytiske formuleringer av Apo A-I Milano:fosfolipidkomplekser ble også tilveiebrakt.
NO20062110A 2003-10-20 2006-05-11 Apo A-IM:POPC-kompleks for anvendelse i en fremgangsmåte for å behandle akutte koronarsyndromer NO339456B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51311603P 2003-10-20 2003-10-20
US51701603P 2003-11-03 2003-11-03
US57112904P 2004-05-14 2004-05-14
PCT/US2004/034800 WO2005041866A2 (en) 2003-10-20 2004-10-19 Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes

Publications (2)

Publication Number Publication Date
NO20062110L true NO20062110L (no) 2006-07-18
NO339456B1 NO339456B1 (no) 2016-12-12

Family

ID=34557347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062110A NO339456B1 (no) 2003-10-20 2006-05-11 Apo A-IM:POPC-kompleks for anvendelse i en fremgangsmåte for å behandle akutte koronarsyndromer

Country Status (24)

Country Link
US (2) US7435717B2 (no)
EP (1) EP1677597B1 (no)
JP (1) JP2007509157A (no)
KR (3) KR20100101710A (no)
AR (1) AR046126A1 (no)
AU (2) AU2004284932A1 (no)
CA (1) CA2542726C (no)
CO (1) CO5690611A2 (no)
CR (1) CR8352A (no)
EA (1) EA010134B1 (no)
EC (1) ECSP066516A (no)
ES (1) ES2449719T3 (no)
GE (1) GEP20094601B (no)
HK (1) HK1093869A1 (no)
IL (1) IL174301A (no)
MA (1) MA28102A1 (no)
MX (1) MXPA06004362A (no)
NO (1) NO339456B1 (no)
NZ (1) NZ545939A (no)
OA (1) OA13272A (no)
PA (1) PA8615301A1 (no)
PE (1) PE20050438A1 (no)
RS (1) RS20060273A (no)
WO (1) WO2005041866A2 (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8246671B2 (en) 1999-08-09 2012-08-21 Cardiokinetix, Inc. Retrievable cardiac devices
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US8388672B2 (en) 1999-08-09 2013-03-05 Cardiokinetix, Inc. System for improving cardiac function by sealing a partitioning membrane within a ventricle
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
PL372925A1 (en) * 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US20040067873A1 (en) * 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
WO2005097206A2 (en) * 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
JP4880685B2 (ja) * 2005-07-22 2012-02-22 ザ プロクター アンド ギャンブル カンパニー 薬物による不整脈の発生を低減するための組成物
WO2007130724A2 (en) * 2006-02-06 2007-11-15 Northwind Ventures Systems and methods for volume reduction
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
AU2007224175A1 (en) * 2006-03-03 2007-09-13 Activbiotics Pharma Llc Treatment of atherosclerotic disease
DE102007006663A1 (de) * 2007-02-10 2008-08-21 Lts Lohmann Therapie-Systeme Ag Transport von Arzneistoffen über die Blut-Hirn-Schranke mittels Apolipoproteinen
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
US8980296B2 (en) * 2009-02-18 2015-03-17 Cormatrix Cardiovascular, Inc. Compositions and methods for preventing cardiac arrhythmia
AU2010217760B2 (en) 2009-02-27 2015-04-09 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US20100234827A1 (en) * 2009-03-13 2010-09-16 Sigg Daniel C Method of treating heart failure
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US8790242B2 (en) 2009-10-26 2014-07-29 Cardiokinetix, Inc. Ventricular volume reduction
AU2011274238B2 (en) 2010-06-30 2013-09-26 Csl Limited A reconstituted high density lipoprotein formulation and production method thereof
TW201215394A (en) 2010-08-30 2012-04-16 Hoffmann La Roche Tetranectin-apolipoprotein A-I, lipid particles containing it and its use
JP2013538205A (ja) 2010-08-30 2013-10-10 エフ．ホフマン−ラ ロシュ アーゲー テトラネクチン−アポリポタンパク質ａ−ｉ粒子を産生するための方法、それを用いて得られる脂質粒子、及びその使用
BR112013004397A2 (pt) 2010-08-30 2017-06-27 Hoffmann La Roche método para produzir uma partícula de lipídio, a partícula de lipídio em si e seu uso
DK2767546T3 (en) 2011-02-07 2019-02-04 Cerenis Therapeutics Holding Sa Lipoprotein complexes and their preparation and uses
AU2012249324B2 (en) * 2011-04-27 2016-10-06 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein CIII (ApoCIII) expression
WO2012162392A1 (en) 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
CA2838070A1 (en) 2011-08-25 2013-02-28 F. Hoffmann-La Roche Ag Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof
RU2014129505A (ru) * 2011-12-21 2016-02-10 СиЭсЭл ЛИМИТЕД Схема дозирования для составов аполипопротеина
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
AU2014228815B2 (en) 2013-03-15 2019-04-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
HUE039246T2 (hu) * 2013-10-31 2018-12-28 Novo Nordisk As Injekciós készülék tûkanüllel
CA2962747C (en) 2014-09-28 2023-02-28 Cardiokinetix, Inc. Apparatuses for treating cardiac dysfunction
US10668015B2 (en) * 2015-01-20 2020-06-02 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
DK3341044T3 (da) * 2015-08-25 2020-02-17 Novo Nordisk As Medicinsk injektionsindretning med et rensningskammer
US10898330B2 (en) 2017-03-28 2021-01-26 Edwards Lifesciences Corporation Positioning, deploying, and retrieving implantable devices
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US6306433B1 (en) * 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
PL372925A1 (en) * 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US20040067873A1 (en) * 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
CA2485989A1 (en) * 2002-05-17 2003-11-27 Esperion Therapeutics, Inc. Methods and compositions for the treatment of ischemic reperfusion

Also Published As

Publication number Publication date
WO2005041866A3 (en) 2006-05-18
PA8615301A1 (es) 2005-09-28
EP1677597A4 (en) 2011-08-24
KR20070110561A (ko) 2007-11-19
AR046126A1 (es) 2005-11-23
MA28102A1 (fr) 2006-08-01
EP1677597B1 (en) 2014-01-08
JP2007509157A (ja) 2007-04-12
ECSP066516A (es) 2006-11-24
EP1677597A2 (en) 2006-07-12
US7435717B2 (en) 2008-10-14
RS20060273A (sr) 2008-09-29
CO5690611A2 (es) 2006-10-31
HK1093869A1 (en) 2007-03-16
AU2011202014B2 (en) 2012-06-14
EA200600548A1 (ru) 2006-10-27
OA13272A (en) 2007-01-31
MXPA06004362A (es) 2006-09-04
KR20060080227A (ko) 2006-07-07
GEP20094601B (en) 2009-02-10
AU2004284932A1 (en) 2005-05-12
WO2005041866A2 (en) 2005-05-12
CA2542726A1 (en) 2005-05-12
ES2449719T3 (es) 2014-03-20
CA2542726C (en) 2012-05-15
AU2011202014A1 (en) 2011-05-26
PE20050438A1 (es) 2005-06-14
NZ545939A (en) 2008-08-29
US20080293633A1 (en) 2008-11-27
IL174301A0 (en) 2006-08-01
CR8352A (es) 2007-03-02
NO339456B1 (no) 2016-12-12
EA010134B1 (ru) 2008-06-30
KR20100101710A (ko) 2010-09-17
US20050142180A1 (en) 2005-06-30
IL174301A (en) 2013-09-30

Similar Documents

Publication Publication Date Title
NO20062110L (no) Farmasoytiske formuleringer fremgangsmater og doseringsregimer for behandling og forebygging av akutte hjertesviktsyndromer.
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
NO20055605L (no) Kombinasjonsprodukter for behandling av sykdommer som omfatter celleprofilerasjon, migrasjon eller apotose av myelomaceller, eller angiogenese
IS8395A (is) Fjölvasýklískar karboxýlsýrur og asýlsúlfónamíð sem hindrar á lifrabólgu C eftirmyndun
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
LU92642I2 (fr) Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid)
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
DE602004025726D1 (de) Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
WO2003079979A3 (en) Method for treating congestive heart failure
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
RU2017136295A (ru) Фиксированные комбинации и составы, содержащие етс1002 и один или более статинов, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
NO20064753L (no) Kombinasjonsterapi
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
ATE502637T1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
ATE554764T1 (de) Wirkungsvolle vereinfachte derivate von immunosuppressiva
ATE293602T1 (de) 2-aminopyridine als inhibitoren von cyclooxygenase-2
TNSN06114A1 (fr) Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees